daptomycin for injection，Cubicin

Effects and efficacy:
Complicated skin and soft tissue infections (cSSSI): Treatment of complicated skin and soft tissue infections in adults and children (1-17 years old) caused by Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subspecies equisimilis and Enterococcus faecalis (only for vancomycin-sensitive strains) that are sensitive to this product. Bloodstream infection (bacteremia) caused by Staphylococcus aureus (including methicillin-sensitive and methicillin-resistant) in adults, and concomitant right-sided infective endocarditis. Bloodstream infection (bacteremia) caused by Staphylococcus aureus in children (1-17 years old).

Dosage and administration:
Duration of administration: When this product is injected intravenously in adults, the injection duration should be 2 minutes: When injected intravenously in adults for 2 minutes, reconstitute this product to a concentration of 50 mg/ml for administration. When this product is administered intravenously, the duration of the infusion should be 30 minutes: When an adult patient is administered intravenously for 30 minutes, the reconstituted product (concentration 50mgl/ml) is further diluted with 0.9% sodium chloride injection using aseptic technique before administration. Pediatric patients (1-17 years old) are administered intravenously for 30 minutes or 60 minutes. Unlike adult patients, this product cannot be administered to pediatric patients through a 2-minute intravenous injection; For pediatric patients (1-6 years old), intravenous infusion for 60 minutes: The reconstituted product (concentration 50mg/ml) should be diluted one step in an infusion bag of 25 ml 0.9% sodium chloride injection using aseptic technique. The infusion rate should be maintained at 0.42ml/minute within 60 minutes. For pediatric patients (7-17 years old), intravenous infusion for 30 minutes; The reconstituted product (concentration 50m/ml) should be further diluted in an infusion bag of 50 ml 0.9% sodium chloride injection using aseptic technique. The infusion rate should be maintained at 1.67 ml/min within 30 minutes of incision. Dosage Complicated Skin and Soft Tissue Infections: Injection: Dissolve this product in 0.9% sodium chloride injection at a dose of 4 mg/kg and administer intravenously once every 24 hours for 7 to 14 days. Pediatric Patients: Table 1 below shows the recommended dosing regimen based on the age of pediatric patients. Dissolve this product in 0.9% sodium chloride injection and administer intravenously once every 24 hours for a maximum of 14 days. 12-17 years old 5 mg/kg, once every 24 hours, intravenous drip for 30 minutes 7-11 years old 7 mg/kg, once every 24 hours, intravenous drip for 30 minutes 2-6 years old 9 mg/kg, once every 24 hours, intravenous drip for 60 minutes 1-<2 years old 10 mg/kg, once every 24 hours, intravenous drip for 60 minutes Note: Recommended dosing regimen for pediatric patients with normal renal function (1 to 17 years old). Dosage adjustment regimen for pediatric patients with renal impairment has not been established. Adult Staphylococcus aureus (including methicillin-sensitive and methicillin-resistant) bloodstream infection (bacteremia), and concomitant right-sided infective endocarditis: Dissolve this product in 0.9% sodium chloride injection at a dose of 6 mg/kg and administer intravenously once every 24 hours for a course of 2-6 weeks. There is limited safety data for the use of this product for more than 28 days. In a Phase Ill clinical trial completed abroad, a total of 14 patients received treatment with this product for more than 28 days. Staphylococcus aureus bloodstream infection (bacteremia) in pediatric patients (1-17 years old): Table 2 recommends dosing regimens based on the age of pediatric patients. Dissolve this product in 0.9% sodium chloride injection and administer intravenously once every 24 hours for a maximum of 42 days. 12-17 years old 7 mg/kg, once every 24 hours, intravenous drip for 30 minutes 7-11 years old 9 mg/kg, once every 24 hours, intravenous drip for 30 minutes 1-6 years old 12 mg/kg, once every 24 hours, intravenous drip for 60 minutes Note: Recommended dosing regimen for pediatric patients with normal renal function (1-17 years old). Dosage adjustment for pediatric patients with renal impairment has not been established. Medication for patients with renal impairment Adults with creatinine clearance (CLCR) < 30ml, including those receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) The recommended dosing regimen is 4 mg/kg (complicated skin and soft tissue infections) or 6 mg/kg (Staphylococcus aureus bloodstream infections) every 48 hours. If possible, give this product after completing hemodialysis on the day of blood induction, the regimen is as follows: for creatinine clearance ≥ 30ml/min: 4mg/kg every 24 hours for complicated skin and soft tissue infection; 6mg/kg every 24 hours for Staphylococcus aureus bloodstream infection; for creatinine clearance <30ml/min, including hemodialysis and CAPD: 4mg/kga every 48 hours for complicated skin and soft tissue infection; 6mg/kgaaa every 48 hours for Staphylococcus aureus bloodstream infection. If possible, give this product after completing hemodialysis on the day of hemodialysis. The dosing regimen for children with renal impairment has not been established.

Drug contraindications:
Allergic to this product is prohibited for children to use with caution during pregnancy and lactation
Related dosage forms:
Injection